about
Human ophthalmomyiasis interna caused by Hypoderma tarandi, Northern CanadaNovel fastidious, partially acid-fast, anaerobic Gram-positive bacillus associated with abscess formation and recovered from multiple medical centers.Clonal Clusters and Virulence Factors of Group C and G Streptococcus Causing Severe Infections, Manitoba, Canada, 2012-2014.First description of an extended-spectrum-beta-lactamase-producing multidrug-resistant Escherichia fergusonii strain in a patient with cystitis.Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008).Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections.Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases.In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009.Pasteurella species peritoneal dialysis-associated peritonitis: Household pets as a risk factor.Matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF/MS)-based identification of pathogens from positive blood culture bottles.Empyema caused by Clostridium bifermentans: A case reportEpidemiology of vancomycin-resistant enterococci in Canadian hospitals (CANWARD study, 2007 to 2013).A Canadian immigrant with coinfection of Strongyloides stercoralis and human T-lymphotropic virus 1.Gardnerella vaginalis bacteremia in a previously healthy man: case report and characterization of the isolate.A case of vertical transmission of Chagas disease contracted via blood transfusion in Canada.ESBL genotypes in fluoroquinolone-resistant and fluoroquinolone-susceptible ESBL-producing Escherichia coli urinary isolates in ManitobaEvaluation of an algorithmic approach in comparison with the Illumigene assay for laboratory diagnosis of Clostridium difficile infectionDifferences in antimicrobial susceptibility in Escherichia coli from Canadian intensive care units based on regional and demographic variables.Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections.The diabetic foot clinic: not a significant source for acquisition of methicillin-resistant Staphylococcus aureus.In Vitro activity of fosfomycin against Escherichia coli isolated from patients with urinary tract infections in Canada as part of the CANWARD surveillance study.In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012.The microbiology of endophthalmitis: global trends and a local perspective.Re-evaluation of rejection criteria for endotracheal tube (ETT) specimens from adult patients.Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia.Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.Quintessential Culture-Negative Endocarditis.Antimicrobial susceptibility of clinical isolates of Neisseria gonorrhoeae to alternative antimicrobials with therapeutic potential.Successful treatment of pulmonary blastomycosis with continuously infused amphotericin B deoxycholate after failure with liposomal amphotericin B.Characterization of isolates of Eisenbergiella tayi, a strictly anaerobic Gram-stain variable bacillus recovered from human clinical materials in Canada.Multifaceted antibiotic treatment analysis of methicillin-sensitive Staphylococcus aureus bloodstream infections.Microbiological Trends and Antimicrobial Resistance in Peritoneal Dialysis-Related Peritonitis, 2005 to 2014.CHROMagar Orientation medium reduces urine culture workload.Changing trends in β-hemolytic streptococcal bacteremia in Manitoba, Canada: 2007-2012.Evaluation of MRSASelect (™) chromogenic medium for the early detection of methicillin-resistant Staphylococcus aureus from blood cultures.Interim estimates of 2013/14 influenza clinical severity and vaccine effectiveness in the prevention of laboratory-confirmed influenza-related hospitalisation, Canada, February 2014.Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006.
P50
Q24647030-24EA8E82-2674-47DF-8C2F-ADBB36A4761FQ30666299-63E42A35-2703-469C-B8DD-AA5AF246B6D5Q33908032-9CD6D808-F2EB-4EE0-A349-A033DA9E3BF7Q33909472-F19C3659-DC44-4882-BF2E-E03D27B3CFBBQ34017518-68CD2D33-A866-4717-9C88-A653351ECC8BQ34290139-51F048DA-EF91-4077-AC6F-AE3B3C6545C6Q34393008-2B246EFB-F690-41B9-9BBA-A1E562116528Q34402134-32AF4BF1-F87C-4D8A-B760-8F7DB289200FQ34752032-F81602E3-25CF-4556-BC80-6C9B6060CA3AQ34932937-7ACD87DC-F5ED-4DAD-B216-1DEBB1DD54F7Q35004919-286B6E31-B3E6-4DE2-A893-E96BEB3DFEBBQ35158136-CE3BC90F-ABBB-41C7-A573-7B55419818C9Q35335769-7C16BD6C-7FF9-4B9D-A608-6B53F4BBDCACQ35569869-A4C2068B-91DC-4CEA-B240-608487DF4A08Q35746080-17601719-0B17-41F6-8D4F-D192E2677CD7Q35944597-3C0227FE-556D-4EE1-BB1E-5ECE60452117Q36452537-E1E5C570-74F0-4CDD-BE3E-28A257C7B92DQ36777537-F837B9A4-A2A7-4772-AFD6-DABD75765CF8Q36871054-4DDD7F5A-23D4-4C52-9847-9F463D092844Q36884365-9123DD93-AB01-4F48-A31D-71E1B19EAD10Q37018234-B0996D7E-F06E-4C55-9BD1-BD58650DA9D8Q37077627-637EEC4A-6A66-4968-81B3-2410260D1763Q37401489-F5735076-61C7-4425-A5C1-A7973D704795Q37544647-757D509B-7C2D-4CA2-87DC-BC3888AA81C5Q37712980-9408F9FD-1A0F-4B7F-974A-502CD4AC92F0Q38016095-97D7C958-ADDB-48F5-ADA0-61F3473FDB96Q38018894-0567D88B-CC7E-495B-A671-893260D07971Q38099393-1491B5AC-1959-4AE0-97B5-3512914B2D26Q38352171-55E9F2BD-5C3A-465D-B3A7-BCBBDC607C06Q40140448-07E9A8BF-8697-40AE-8792-9E855E276C58Q40212540-82048470-0517-43F1-8D03-B374B623B826Q40247785-02A054DE-5044-4BB0-ABCC-29963655D817Q40300169-02471AFF-5EDA-43D6-B70B-D0C4FB17409DQ40478950-BA1AFE7F-25A7-41F9-993D-F791FDB485D9Q40507755-C46101D4-0EAF-4CD9-A019-6DBAB03300D8Q41158811-A4F82A32-9709-405E-92CE-CA9CAB884B17Q41658132-CAC25128-8D7D-4D5C-BD66-8FD7E085F8F2Q41896768-0811F0EA-71FB-49E5-9938-A8477B045470Q42231714-E4264D6A-4703-47F0-BAED-ECFBCA7E4097Q43422890-67BD59E4-CFF5-4CE6-BF4E-10359994B9C0
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Philippe Lagacé-Wiens
@ast
Philippe Lagacé-Wiens
@en
Philippe Lagacé-Wiens
@es
Philippe Lagacé-Wiens
@nl
type
label
Philippe Lagacé-Wiens
@ast
Philippe Lagacé-Wiens
@en
Philippe Lagacé-Wiens
@es
Philippe Lagacé-Wiens
@nl
prefLabel
Philippe Lagacé-Wiens
@ast
Philippe Lagacé-Wiens
@en
Philippe Lagacé-Wiens
@es
Philippe Lagacé-Wiens
@nl
P106
P31
P496
0000-0002-5826-2869